|
BRIEF-Japan approves GlaxoSmithkline's asthma drug Nucala
Reuters March 29 Glaxosmithkline Plc. * Receives marketing authorisation for nucala (mepolizumab) in Japan. * Nucala is licensed in japan for adults and adolescents aged 12 years or older Source text for Eikon: Further company coverage: (Reporting By London … |
View full post on asthma – Google News